Fibrinolysis News and Research

RSS

T2Hemostasis provides reliable and rapid results when compared to conventional systems

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA.

20 Jul 2012

US emergency angioplasty guidelines ‘not sufficient’

The coordinated regional system of care for severe myocardial infarction in North Carolina, USA, should be established nationally, researchers say in Circulation.

7 Jun 2012

Ethanol, nonalcoholic compounds in red wine may reduce risk of vascular disease

Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.

18 Jan 2012

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

Omeros receives exclusive license for new series of antifibrinolytic agents

Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents. These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding.

6 Jan 2011

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

Helicopter emergency medical services can be a life saver for patients needing immediate care. But, according to a University of Cincinnati study, the process of activating them often delays treatment beyond recommended times.

10 Dec 2010

ASH to host annual meeting for blood disorders at Orange Convention Center

The American Society of Hematology (ASH) will host its 52nd annual meeting at the Orange County Convention Center in Orlando, FL, December 4-7. More than 20,000 attendees are expected for this event, which will highlight emerging research trends in the diagnosis, treatment, and understanding of blood disorders.

1 Dec 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

Antithrombotic therapy increases bleeding risk in CAD patients: Research

Antithrombotic therapy using antiplatelet and anticoagulant agents is the cornerstone of treatment for acute and chronic coronary artery disease (CAD), yet it is also associated with an increased risk of bleeding. It is paradoxical that elderly patients, the most likely population to develop CAD, are those that suffer most from bleeding complications.

31 Aug 2010

Health care system delay increases death risk in heart attack patients

For patients with a certain type of heart attack, delay in the time between first contact with emergency medical service to initiation of therapy such as balloon angioplasty is associated with an increased risk of death, according to a study in the August 18 issue of JAMA.

18 Aug 2010

Severity of appendicitis can be predicted from blood sample, shows thesis

The symptoms of appendicitis are often diffuse and it can be difficult to obtain an accurate diagnosis early in the course of the disease. It may be possible to predict the severity from a blood sample, and in this way determine the treatment on an individual basis. This is the conclusion of a thesis presented at the University of Gothenburg, sweden.

21 Jun 2010

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.

2 Jun 2010

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

23 Apr 2010

Artificial human skin with dermis made from fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained. This pioneering finding will allow the clinical use of human skin and its use in many laboratory tests on biological tissues -which, additionally, would avoid the use of laboratory animals.

20 Apr 2010

ASH Annual Meeting to showcase latest research and treatments for blood disorders

The American Society of Hematology (ASH), the world's largest professional association of blood specialists, expects more than 20,000 attendees at the 51st ASH Annual Meeting from December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. The meeting will showcase the latest research and treatments for blood disorders.

2 Dec 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009